Popular Press
Predicting Response to Vismodegib in Locally Advanced Basal Cell Carcinoma
JNCNN 360
(2021)
Abstract
In a recent letter to the editor, Maria Concetta Fargnoli, MD, of L’Aquila, L’Aquila, Italy, and colleagues shared their real-world, multicenter, retrospective study findings aimed at evaluating the clinical determinants of complete response to the Hedgehog pathway inhibitor vismodegib in patients with locally advanced basal cell carcinoma. Their work, published in the Journal of the European Academy of Dermatology and Venereology, showed that dosing changes compromised complete response rates.
Disciplines
Publication Date
September 27, 2021
Citation Information
Noelle L Cutter. "Predicting Response to Vismodegib in Locally Advanced Basal Cell Carcinoma" JNCNN 360 (2021) Available at: http://works.bepress.com/noelle-cutter/74/